SG10201913225SA - Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor - Google Patents

Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor

Info

Publication number
SG10201913225SA
SG10201913225SA SG10201913225SA SG10201913225SA SG10201913225SA SG 10201913225S A SG10201913225S A SG 10201913225SA SG 10201913225S A SG10201913225S A SG 10201913225SA SG 10201913225S A SG10201913225S A SG 10201913225SA SG 10201913225S A SG10201913225S A SG 10201913225SA
Authority
SG
Singapore
Prior art keywords
aggrus
clec
binding
screening
domain
Prior art date
Application number
SG10201913225SA
Other languages
English (en)
Inventor
Naoya Fujita
Takaya SEKIGUCHI
Satoshi Takagi
Original Assignee
Japanese Found For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Found For Cancer Res filed Critical Japanese Found For Cancer Res
Publication of SG10201913225SA publication Critical patent/SG10201913225SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201913225SA 2015-07-15 2016-07-11 Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor SG10201913225SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015140998 2015-07-15
JP2015211883 2015-10-28

Publications (1)

Publication Number Publication Date
SG10201913225SA true SG10201913225SA (en) 2020-02-27

Family

ID=57757420

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913225SA SG10201913225SA (en) 2015-07-15 2016-07-11 Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
SG11201800326YA SG11201800326YA (en) 2015-07-15 2016-07-11 Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201800326YA SG11201800326YA (en) 2015-07-15 2016-07-11 Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor

Country Status (8)

Country Link
US (2) US10730939B2 (ja)
EP (1) EP3323831B1 (ja)
JP (2) JP6803840B2 (ja)
KR (1) KR20180023951A (ja)
CN (2) CN113336852A (ja)
ES (1) ES2949317T3 (ja)
SG (2) SG10201913225SA (ja)
WO (1) WO2017010463A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913225SA (en) * 2015-07-15 2020-02-27 Japanese Found For Cancer Res Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
CN106947744B (zh) * 2017-03-14 2020-05-05 福州迈新生物技术开发有限公司 一株分泌抗平足蛋白单克隆抗体的杂交瘤细胞株及其应用
JP6847434B2 (ja) * 2017-03-30 2021-03-24 国立大学法人東北大学 抗ポドプラニン抗体
US20210132072A1 (en) 2017-10-26 2021-05-06 Vib Vzw Podoplanin positive macrophages
US11530266B2 (en) 2019-03-15 2022-12-20 Japanese Foundation For Cancer Research Anti-podoplanin antibody
WO2020188836A1 (ja) 2019-03-15 2020-09-24 公益財団法人がん研究会 抗ポドプラニン抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721633B2 (ja) 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
CN1778822A (zh) * 2004-11-24 2006-05-31 中国人民解放军第二军医大学 C型凝集素样受体l1的单克隆抗体及其制备和应用
KR101956566B1 (ko) 2011-03-22 2019-03-11 고에키자이단호진 간겐큐카이 마우스 항Ａｇｇｒｕｓ 모노클로날 항체
JP2013071916A (ja) 2011-09-28 2013-04-22 General Incorporated Association Pharma Valley Project Supporting Organization ３−アリールオキシクロモン化合物を有効成分とする血小板凝集抑制剤
JP6473418B2 (ja) * 2013-10-10 2019-02-20 幸成 加藤 抗ポドプラニン抗体
SG10201913225SA (en) * 2015-07-15 2020-02-27 Japanese Found For Cancer Res Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor

Also Published As

Publication number Publication date
JP2021046417A (ja) 2021-03-25
JP7122361B2 (ja) 2022-08-19
ES2949317T3 (es) 2023-09-27
CN107849138B (zh) 2021-06-29
EP3323831A1 (en) 2018-05-23
SG11201800326YA (en) 2018-02-27
EP3323831A4 (en) 2019-02-27
US20180237518A1 (en) 2018-08-23
JPWO2017010463A1 (ja) 2018-07-05
CN113336852A (zh) 2021-09-03
CN107849138A (zh) 2018-03-27
EP3323831B1 (en) 2023-04-12
KR20180023951A (ko) 2018-03-07
US10730939B2 (en) 2020-08-04
JP6803840B2 (ja) 2020-12-23
US20210009683A1 (en) 2021-01-14
WO2017010463A1 (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
IL268527A (en) Bispecific antibodies bind PD1 and LAG3 specifically
HK1256365A1 (zh) 對pd1和tim3特異性的雙特異性抗體
IL263542A (en) Bispecific antibodies inhibit immunological checkpoint
ZA201803669B (en) Antibodies specifically binding pd-1 and their uses
SG11201705252UA (en) Anti-pd-1 monoclonal antibodies and obtaining method thereof
ZA201908549B (en) Checkpoint inhibitor bispecific antibodies
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter
SG10201913225SA (en) Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
SG11201610446XA (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201709908QA (en) Method for quantifying monoclonal antibody
ZA201902120B (en) Antibody specifically binding to pd-1 and functional fragment thereof
HK1256804A1 (zh) 抗cd154抗體及其使用方法
IL252008A0 (en) Methods for producing bispecific domains, variants of antibodies and their use
ZA202003858B (en) Monoclonal antibodies and methods for using same
SG11202101922YA (en) Highly versatile method for granting new binding specificity to antibody
SG11201705632UA (en) Bispecific antibody binding to trailr2 and psma
GB201620411D0 (en) Method and composition for determining specific antibody responses to species of filovirus
GB201621591D0 (en) Antibody molecules and method
IL248458A0 (en) Cry1ca-specific monoclonal antibodies and related detection methods
GB201516008D0 (en) OX40L antibodies and uses thereof